Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - ACELRX PHARMACEUTICALS INCex_176480.htm
EX-31.2 - EXHIBIT 31.2 - ACELRX PHARMACEUTICALS INCex_176479.htm
EX-31.1 - EXHIBIT 31.1 - ACELRX PHARMACEUTICALS INCex_176478.htm
EX-21.2 - EXHIBIT 21.2 - ACELRX PHARMACEUTICALS INCex_176476.htm
EX-10.17 - EXHIBIT 10.17 - ACELRX PHARMACEUTICALS INCex_177094.htm
EX-10.16 - EXHIBIT 10.16 - ACELRX PHARMACEUTICALS INCex_177092.htm
EX-4.1 - EXHIBIT 4.1 - ACELRX PHARMACEUTICALS INCex_177093.htm
10-K - FORM 10-K - ACELRX PHARMACEUTICALS INCacrx20191231_10k.htm

 

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the following Registration Statements:

 

 

(i)

Registration Statements on Form S-8 (Nos. 333-230139, 333-223535, 333-216492, 333-202709, 333-194634 and 333-187206) pertaining to the 2011 Equity Incentive Plan,

 

 

(ii)

Registration Statements on Form S-8 (Nos. 333-209998 and 333-180334) pertaining to the 2011 Equity Incentive Plan and 2011 Employee Stock Purchase Plan,

 

 

(iii)

Registration Statement on Form S-8 (No. 333-172409) pertaining to the 2006 Stock Plan, 2011 Equity Incentive Plan and 2011 Employee Stock Purchase Plan, and

 

 

(iv)

Registration Statement on Form S-3 (No. 333-218506)

 

of our reports dated March 16, 2020 with respect to the consolidated financial statements and the effectiveness of internal control over financial reporting of AcelRx Pharmaceuticals, Inc., which appear in this Annual Report on Form 10-K.

 

/s/ OUM & CO. LLP

 

San Francisco, California

March 16, 2020